Form 4: ASMB Chief Manufacturing Officer Equity Grant & Tax Sales

ASSEMBLY BIOSCIENCES' Chief Manufacturing Officer, Nicole S. White, received a restricted stock unit grant and sold shares to cover tax obligations.

Summary

• Nicole S. White, Chief Manufacturing Officer of ASSEMBLY BIOSCIENCES, Inc. (ASMB), was granted 26,000 restricted stock units (RSUs) on March 29, 2026.
• These RSUs will vest in four equal installments annually on March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030, assuming continuous service.
• 65% of the RSUs were granted, with the remaining 35% contingent upon stockholder approval of an amendment to the company's Amended and Restated 2018 Stock Incentive Plan.
• On March 30, 2026, Ms. White sold a total of 197 shares of common stock (188 shares at a weighted average price of $26.6502 and 9 shares at a weighted average price of $27.49).
• These sales were non-discretionary "sell-to-cover" transactions mandated by the Compensation Committee to satisfy tax withholding obligations related to RSU vesting.
• Following these transactions, Ms. White directly beneficially owns 37,477 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine executive compensation event. The RSU grant is a positive for executive alignment, while the associated tax-related stock sales are non-discretionary and thus neutral in sentiment.

Positives

• Grant of 26,000 restricted stock units to a key executive, aligning management's interests with long-term shareholder value.
• The equity grant serves as an incentive for continued service and performance of the Chief Manufacturing Officer.

Negatives

• Sales of common stock by an insider, even if for tax purposes, reduce their direct ownership.
• A portion (35%) of the RSU grant is contingent on stockholder approval of a plan amendment, introducing a slight uncertainty regarding the full grant.

Risks

• The full RSU grant is contingent on stockholder approval of an amendment to the 2018 Stock Incentive Plan, which may not be secured.
• Future stock price fluctuations could impact the value of the unvested RSUs and the proceeds from any future "sell-to-cover" transactions.

Future Outlook

The vesting schedule for the restricted stock units extends through March 29, 2030, indicating a long-term incentive structure for the Chief Manufacturing Officer. The remaining 35% of the RSU grant is contingent on future stockholder approval of an amendment to the company's stock incentive plan.

Management Comments

• The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units.
• The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a 'sell-to-cover' transaction and does not represent a discretionary transaction by the reporting person.

Industry Context

StockSavvy.ai notes that equity grants like restricted stock units are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, aiming to align executive incentives with long-term company performance and shareholder value. The 'sell-to-cover' mechanism for tax obligations is also a common practice, distinguishing these sales from discretionary insider selling.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) with a multi-year vesting schedule is a common practice in the biotech sector, comparable to compensation structures at companies like Gilead Sciences or Amgen, which also utilize long-term equity incentives to retain key talent.
• The 'sell-to-cover' transaction for tax withholding is a standard administrative procedure across most publicly traded companies, including peers in the life sciences industry, ensuring compliance with tax laws without requiring executives to use personal funds for tax liabilities arising from equity vesting.
• The contingency of a portion of the RSU grant on stockholder approval for an increased share pool is also a typical corporate governance step, ensuring that equity dilution is approved by shareholders, similar to practices seen at companies like Moderna or BioNTech when expanding their incentive plans.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for long-term value alignment with management due to RSU grant; minor, non-discretionary dilution from 'sell-to-cover' sales; potential future dilution if the 2018 Stock Incentive Plan amendment is approved.
• Employees (Executives): Nicole S. White receives significant equity compensation, incentivizing continued service and performance.

Next Steps

• Stockholder approval of an amendment to the 2018 Stock Incentive Plan for the remaining 35% of the RSU grant.
• Vesting of RSUs in four equal installments on March 29, 2027, 2028, 2029, and 2030.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation and tax-related stock sales, which are not indicative of fundamental changes in the company's operations or outlook. The RSU grant aligns executive interests with long-term performance, while the sales are non-discretionary. Therefore, the filing itself does not provide a basis for a change in investment recommendation, suggesting a 'hold' position for existing investors.

Keywords

ASMB, ASSEMBLY BIOSCIENCES, Form 4, Insider Trading, Restricted Stock Units, RSU Grant, Equity Compensation, Executive Compensation, Stock Sale, Tax Withholding, Chief Manufacturing Officer